In this setting, the use of EZH2-mediated histone modification (GSK126) and DNA-methylation (5-AZA dC) inhibitors removes the Cxcl9 and Cxcl10 transcription repression in ovarian cancer cells, thus increasing the CD8 T-cell recruitment in the tumor, slowing down the tumor growth and improving the anti-PD-L1 therapy efficacy [73]. Here, CXCL9 is linked to ovarian cancer.